{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:17:29Z","timestamp":1788265049188,"version":"build-2803163510"},"reference-count":36,"publisher":"Bioscientifica","issue":"8","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) is an emerging and promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas refractory to conventional therapies. Its use is supported by the frequent expression of somatostatin receptors (SSTRs), predominantly SSTR2, in pituitary tumour cells, enabling selective delivery of \u03b2-emitting radionuclides, such as 177Lu-DOTATATE and 90Y-DOTATOC, resulting in targeted antitumour and antisecretory effects. This narrative review summarises current limited evidence on PRRT efficacy and safety in aggressive pituitary tumours. Successful outcomes have been reported in some cases in terms of tumour growth reduction and\/or hormonal reduction or relief of mass-effect-related symptoms. PRRT-related adverse events are mostly mild and transient, predominantly haematological, with clinically significant renal toxicity uncommon when amino acid nephroprotection is used. Preserved pituitary function and no clinically significant PRRT-induced hypopituitarism have been reported. Overall, PRRT represents a biologically rational and potentially effective option for selected patients with SSTR-positive aggressive PitNETs after failure of previous therapies.<\/jats:p>","DOI":"10.1530\/erc-26-0109","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:15:31Z","timestamp":1786464931000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy"],"prefix":"10.1530","volume":"33","author":[{"given":"Francesco","family":"Ferra\u00f9","sequence":"first","affiliation":[{"name":"Endocrinology Unit, University Hospital \u201cG. Martino\u201d 1 , ,","place":["Messina, Italy"]},{"name":"Department of Human Pathology of Adulthood and Childhood \u201cG. Barresi\u201d, University of Messina 2 , ,","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Sofia","family":"Blanca","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital \u201cG. Martino\u201d 1 , ,","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1452-9340","authenticated-orcid":true,"given":"Carla Paola","family":"Costa","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital \u201cG. Martino\u201d 1 , ,","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital \u201cG. Martino\u201d 1 , ,","place":["Messina, Italy"]},{"name":"Department of Human Pathology of Adulthood and Childhood \u201cG. Barresi\u201d, University of Messina 2 , ,","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026090107413209100_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13302","article-title":"The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors","volume":"35","author":"Casar-Borota","year":"2025","journal-title":"Brain Pathol"},{"key":"2026090107413209100_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.wneu.2016.09.092","article-title":"Aggressive pituitary adenomas: the dark side of the moon","volume":"97","author":"Priola","year":"2017","journal-title":"World Neurosurg"},{"key":"2026090107413209100_bib3","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026090107413209100_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026090107413209100_bib5","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0338","article-title":"Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review","volume":"30","author":"Raymond","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026090107413209100_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-024-02736-8","article-title":"Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors","volume":"147","author":"Lin","year":"2024","journal-title":"Acta Neuropathol"},{"key":"2026090107413209100_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090107413209100_bib8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"2026090107413209100_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624686","article-title":"Multimodal non-surgical treatments of aggressive pituitary tumors","volume":"12","author":"Nakano-Tateno","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026090107413209100_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J Neurooncol"},{"key":"2026090107413209100_bib11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","article-title":"SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases","volume":"118","author":"Bode","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2026090107413209100_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection","volume":"41","author":"Touma","year":"2017","journal-title":"J Clin Neurosci"},{"key":"2026090107413209100_bib13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ph14090872","article-title":"Peptide receptor radionuclide therapy and primary brain tumors: an overview","volume":"14","author":"Cimini","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026090107413209100_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/jcm8081107","article-title":"Emerging and novel treatments for pituitary tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"J Clin Med"},{"key":"2026090107413209100_bib15","article-title":"Treatment of an aggressive gonadotroph pituitary neuroendocrine tumor with 177Lutetium DOTATATE radionuclide therapy","volume":"2","author":"Gandhi","year":"2024","journal-title":"JCEM Case Rep"},{"key":"2026090107413209100_bib16","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1210\/clinem\/dgaa649","article-title":"Approach to the treatment of a patient with an aggressive pituitary tumor","volume":"105","author":"Lin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090107413209100_bib17","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/cas.15327","article-title":"Neuroendocrine tumor theranostics","volume":"113","author":"Ichikawa","year":"2022","journal-title":"Cancer Sci"},{"key":"2026090107413209100_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-026-10063-4","article-title":"Functional pituitary adenoma imaging","author":"Hesse","year":"2026","journal-title":"Rev Endocr Metab Disord"},{"key":"2026090107413209100_bib19","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3390\/cancers14081914","article-title":"Diagnostic value of radiolabelled somatostatin analogues for neuroendocrine tumour diagnosis: the benefits and drawbacks of [64Cu]Cu-DOTA-TOC","volume":"14","author":"Vahidfar","year":"2022","journal-title":"Cancers"},{"key":"2026090107413209100_bib20","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00259-025-07726-w","article-title":"Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"53","author":"Zampella","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090107413209100_bib21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1159\/000538523","article-title":"Treatment and long-term safety outcomes of peptide receptor radionuclide therapy for metastatic neuroendocrine tumours: an asian experience","volume":"114","author":"Tham","year":"2024","journal-title":"Neuroendocrinology"},{"key":"2026090107413209100_bib22","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026090107413209100_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5812\/ijem.4313","article-title":"Diagnosis of men-I syndrome on (68)Ga-DOTANOC PET-CT and role of peptide receptor radionuclide therapy with (177)Lu-DOTATATE","volume":"10","author":"Kumar Gupta","year":"2012","journal-title":"Int J Endocrinol Metab"},{"key":"2026090107413209100_bib24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"key":"2026090107413209100_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","article-title":"Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report","volume":"125","author":"Walig\u00f3rska-Stachura","year":"2016","journal-title":"J Neurosurg"},{"key":"2026090107413209100_bib26","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s11102-011-0373-5","article-title":"First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment","volume":"15","author":"Baldari","year":"2012","journal-title":"Pituitary"},{"key":"2026090107413209100_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-007-0038-6","article-title":"Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review","volume":"11","author":"Goglia","year":"2008","journal-title":"Pituitary"},{"key":"2026090107413209100_bib28","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026090107413209100_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"key":"2026090107413209100_bib30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090107413209100_bib31","article-title":"Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor","volume":"5","author":"Wolf","year":"2025","journal-title":"Endocr Oncol"},{"key":"2026090107413209100_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"key":"2026090107413209100_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","article-title":"The use of (68)Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma","volume":"40","author":"Novruzov","year":"2015","journal-title":"Clin Nucl Med"},{"key":"2026090107413209100_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/eci.12010","article-title":"ACTH-secreting Crooke cell carcinoma of the pituitary","volume":"43","author":"Kov\u00e1cs","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"2026090107413209100_bib35","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.3390\/cancers15102710","article-title":"The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary","volume":"15","author":"Marques","year":"2023","journal-title":"Cancers"},{"key":"2026090107413209100_bib36","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1002\/cam4.4345","article-title":"Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours","volume":"10","author":"Elston","year":"2021","journal-title":"Cancer Med"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0109\/523459\/erc-26-0109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0109\/523459\/erc-26-0109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:41:43Z","timestamp":1788262903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/8\/e260109\/77982\/Peptide-receptor-radionuclide-therapy-PRRT-and-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0109","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"e260109"}}